19-Apr-2024
Globe Newswire (Thu, 18-Apr 8:00 AM ET)
TipRanks (Thu, 18-Apr 12:30 AM ET)
Buy Rating for Lantheus Holdings with Strong Growth and Acquisition Potential
TipRanks (Wed, 17-Apr 8:16 PM ET)
Globe Newswire (Thu, 28-Mar 7:30 AM ET)
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
Globe Newswire (Tue, 5-Mar 8:30 AM ET)
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
Globe Newswire (Tue, 5-Mar 8:00 AM ET)
Globe Newswire (Mon, 4-Mar 8:30 AM ET)
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
Globe Newswire (Wed, 28-Feb 8:30 AM ET)
Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
Globe Newswire (Mon, 26-Feb 8:30 AM ET)
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Thu, 22-Feb 7:00 AM ET)
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Lantheus Holdings trades on the NASDAQ stock market under the symbol LNTH.
As of April 19, 2024, LNTH stock price climbed to $63.81 with 760,908 million shares trading.
LNTH has a beta of 0.04, meaning it tends to be less sensitive to market movements. LNTH has a correlation of 0.00 to the broad based SPY ETF.
LNTH has a market cap of $4.37 billion. This is considered a Mid Cap stock.
Last quarter Lantheus Holdings reported $354 million in Revenue and $1.75 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.30.
In the last 3 years, LNTH stock traded as high as $100.85 and as low as $19.30.
The top ETF exchange traded funds that LNTH belongs to (by Net Assets): VTI, IJH, VB, IWM, VXF.
LNTH stock has underperformed the market in the last year with a return of -29.5%, while SPY returned +21.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LNTH shares. However, LNTH has outperformed the market in the last 3 month and 2 week periods, returning +20.2% and +4.9%, while SPY returned +3.0% and -4.5%, respectively. This indicates LNTH has been having a stronger performance recently.
LNTH support price is $60.86 and resistance is $63.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LNTH stock will trade within this expected range on the day.